NeuroSense Therapeutics Ltd. (NRSN) announced Tuesday that it met its primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of its 6-month, randomized, placebo-controlled, double-blind segment the Company's Phase 2b amyotrophic lateral sclerosis (ALS) trial of PrimeC (PARADIGM).
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS - PrimeC, a novel combination therapy, demonstrated efficacy and safety in Phase IIa. | March 21, 2022
Deadly Bacteria Could Be Sharing Antibiotic Resistance Faster Than We Thought
22 JANUARY 2021
Antibiotics have saved countless lives over the decades. Yet to the pathogens they kill, antibiotics are an ancient foe, one they are already adept at fighting.
It turns out the spread of antibiotic resistance might not be as constrained as we assumed, giving more species far easier access to antibiotic resistance than previous models would have us believe.
The findings come from a study carried out by bioinformatics researcher Jan Zrimec from Chalmers University of Technology in Sweden, which looked for signs of mobility among elements of DNA called plasmids.